2010
Pharmacogenetic Testing in the Pediatric Epileptic Population
Sander T, Marcuccilli C, Zembles T, Hines R, Lo S, North P. Pharmacogenetic Testing in the Pediatric Epileptic Population. The FASEB Journal 2010, 24: 568.16-568.16. DOI: 10.1096/fasebj.24.1_supplement.568.16.Peer-Reviewed Original ResearchAdverse drug reactionsAntiepileptic drugsSevere adverse drug reactionsABCB1 genetic variantsChronic neurologic disordersFast Real-Time PCR SystemRecurrent unprovoked seizuresAED therapyPediatric patientsUnprovoked seizuresADR riskDrug reactionsPhysician comfortNeurologic disordersEpileptic populationPharmacogenetic testingTherapeutic windowPharmacogenetic testsPatientsTherapeutic treatmentGenotype resultsReal-time PCR systemGenotyping assaysTherapyGenetic variants
2006
The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
Krueger S, VanDyke J, Williams D, Hines R. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines. Drug Metabolism Reviews 2006, 38: 139-147. PMID: 16684653, DOI: 10.1080/03602530600569919.Peer-Reviewed Original ResearchConceptsMetabolism of tamoxifenBreast cancer therapyHuman liver microsomesFlavin-Containing MonooxygenaseMetabolic activation pathwayEndometrial cancerTamoxifen metabolismN-oxide productionLiver microsomesTamoxifenMetabolic activationDNA adductionCancer therapyActivation pathwayCytochrome P450Detoxication pathwayN-oxygenationRiskMetabolismLow levelsPathwayChemopreventionNeoplasiaTherapyCancer